CD8A and esophageal cancer: In our previous work, we found a similar trend in the analysis of CD3- and CD8-positive lymphocytes in esophageal cancer specimens from the same patient cohort, especially in advanced cases.15 Conversely, CD3- and CD8-positive T-cell (CD3+ and CD8+) expression was analyzed in the same patients, and the higher-density group had a better prognosis, especially in advanced cases (pStages II–IV), although not significantly so (5-year OS, CD3+ high vs. low: 59.8 vs. 37.5%, P = 0.0631; 5-year OS, CD8+ high vs. low: 59.6 vs. 39.6%, P = 0.3160).